Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sep

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer

SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer

Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma

Germline EGFR T790M Associated With Significant Lung Cancer Risk

Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC